



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION




TASP0277308

Item No. 11340

CAS Registry No.: 945725-50-8
Formal Name: 3,4-dichloro-N-[(1R)-1-[4-ethyl-5-[3-(4-methyl-1-piperazinyl)phenoxy]-4H-1,2,4-triazol-3-yl]ethyl]-benzenesulfonamide

MF: C₂₃H₂₈Cl₂N₆O₃S
FW: 539.5
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

TASP0277308 is supplied as a solid. A stock solution may be made by dissolving the TASP0277308 in the solvent of choice, which should be purged with an inert gas. TASP0277308 is sparingly soluble (1-10 mg/ml) in DMSO and slightly soluble (0.1-1 mg/ml) in methanol.

Description

TASP0277308 is a sphingosine-1-phosphate receptor 1 (S1P₁) antagonist (IC₅₀ = 4.2 nM).¹ It is selective for S1P₁ over S1P₃, S1P₄, and S1P₅ (IC₅₀s = >10,000, >10,000, and 8,756 nM, respectively). TASP0277308 inhibits S1P-induced [³⁵S]GTPγS binding and forskolin-induced cAMP production in HEK293 cells expressing human S1P₁ (IC₅₀s = 7.8 and 4.3 nM, respectively). It inhibits S1P-induced migration of CHO cells expressing human S1P₁ (IC₅₀ = 18 nM). *In vivo*, TASP0277308 (100 mg/kg) induces lymphopenia in mice. It reduces bone erosion in a mouse model of collagen-induced arthritis. Intrathecal administration of TASP0277308 (3 or 10 nmol/animal) reduces flinching and guarding behaviors in a mouse model of cancer-induced bone pain.²

References

1. Fujii, Y., Hirayama, T., Ohtake, H., *et al.* Amelioration of collagen-induced arthritis by a novel S1P₁ antagonist with immunomodulatory activities. *J. Immunol.* **188**(1), 206-215 (2012).
2. Grenald, S.A., Doyle, T.M., Zhang, H., *et al.* Targeting the S1P/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation. *Pain* **158**(9), 1733-1742 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/13/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM